Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 3/20 | 1.00 |
| ▸ | NAT1 | P18440 | 1/20 | 0.75 |
| ▸ | PIM1 | P11309 | 7/20 | 0.70 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.70 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 7/20 | 0.62 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
| ▸ | GSK3B | P49841 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | INSR | P06213 | 1/20 | 0.59 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6785383 | 1.00 | IGF1R (1.00) | IGF1RNAT1PIM1PIM2ADAMTS5 | |
| SCHEMBL6923574 | 0.86 | IGF1R (0.74) | IGF1RNAT1PIM1PIM2ADAMTS5 | |
| SCHEMBL6923577 | 0.86 | IGF1R (0.74) | IGF1RNAT1PIM1PIM2ADAMTS5 | |
| SCHEMBL6781138 | 0.86 | NAT1 (1.00) | IGF1RNAT1PIM1ADAMTS5RAB9A | |
| SCHEMBL7962398 | 0.86 | NAT1 (1.00) | IGF1RNAT1PIM1ADAMTS5RAB9A | |
| SCHEMBL12892058 | 0.86 | NAT1 (1.00) | IGF1RNAT1PIM1ADAMTS5RAB9A | |
| SCHEMBL13499584 | 0.86 | IGF1R (0.75) | IGF1RNAT1PIM1PIM2ADAMTS5 | |
| SCHEMBL30990559 | 0.86 | IGF1R (0.75) | IGF1RNAT1PIM1PIM2ADAMTS5 | |
| SCHEMBL20637632 | 0.86 | IGF1R (0.75) | IGF1RNAT1PIM1PIM2HPGD | |
| SCHEMBL20637630 | 0.86 | IGF1R (0.75) | IGF1RNAT1PIM1PIM2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006071255-A9 | BACTERIAL REPLICATION SYSTEMS AND METHODS | REPLIDYNE INC (US) | 2007-02-15 | — | — | WO | disclosed |
| US-6727267-B2 | COMPOUND FOR USE IN THE TREATMENT OF VIRAL DISEASES | TULARIK INC. | 2004-04-27 | — | — | US | disclosed |
| US-20020142290-A1 | Compound for use in the treatment of viral diseases | TULARIK INC. (US) | 2002-10-03 | — | — | US | disclosed |
| WO-2001077091-A2 | NS5B HCV POLYMERASE INHIBITORS | TULARIK INC. (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142290-A1 | Compound for use in the treatment of viral diseases | POLRMT, RNASE1, POLI | IGF1R 4706/4885NAT1 195/4885PIM1 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.